Table 1.

Effects of siRNA/inhibitor treatments on sensory epithelia proliferation

siRNA/inhibitor treatment	Inhibit proliferation	Average fold knockdown	Regeneration pathway/category
CEBPG	Yes	−3.92	AP-1 pathway
JNK inhibitor	Yes
JUND	Yes	^*
BTAF1	Yes	−1.57	AP-1 siRNA commonalities
LRP5	Yes	−5.71
RARA	Yes	−1.41
PAX2	Yes	−1.61	Pax pathway
PAX3	No	−1.61
PAX5	Yes	^*
PAX7	No	−1.72
MYT1L	No	^*	AP-1/Pax siRNA commonalities
WNT4	Yes	−2.27	AP-1/Pax siRNA commonalities
CUTL1	Yes	−1.86	Cell cycle
p27KIP	No	−2.93
ID1	No	−1.48
CBX3	No	−4.15	Polycomb complex
CBX4	No	−1.09
EZH2	No	−1.87
IGF inhibitor	No		Pathway inhibitors
MAPK inhibitor	Yes
SHH inhibitor	No
HRY	No	−1.30	Notch signaling
BCL11A	No	−1.35	Common to all tissues/damage
TRIP15	No	−1.12	Common to all tissues/damage
CTNNB1	No	−2.39	Common to cochlea and utricle
TIME	No	−1.16	Early regeneration
PPARGC1	No	−1.42	Neomycin specific

↵Proliferation phenotypes were quantified for each siRNA knockdown. Inhibition was determined as a significantly lower proliferation index than a GFP siRNA control (p < 0.05). Knockdowns of siRNA targets were confirmed by microarray analysis or (*) endpoint semiquantitative PCR.